University of Kentucky Markey Cancer Center researchers have discovered a genetic biomarker that could help identify patients with glioblastoma most likely to benefit from the cancer drug bevacizumab.
Jul 25, 2025
0
0
A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University ...
Aug 8, 2024
0
43
A study appearing in Cancer Cell uncovers the evolutionary dynamics of glioblastoma recurrence through proteogenomic analysis, offering potential therapeutic avenues.
May 10, 2024
0
38
For patients with recurrent glioblastoma, treatment with chimeric antigen receptor (CAR) T-cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, in addition to the wild-type ...
Mar 23, 2024
0
2
Targeting two brain tumor-associated proteins—rather than one—with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain ...
Mar 13, 2024
0
90
A unique drug derived from oleic acid—which naturally occurs in animal and vegetable fats such as olive oil—has shown promise for patients with an advanced form of the most common type of brain cancer, following a study ...
Feb 22, 2024
0
48
Repeat radiation therapy combined with the monoclonal antibody drug bevacizumab extended progression-free survival in patients with recurrent glioblastoma, according to findings from a recent clinical trial published in the ...
Apr 10, 2023
0
21
A subcutaneously implanted, catheter-pump system capable of chronic convection-enhanced delivery (CED) of topotecan is well tolerated and active for patients with recurrent glioblastoma, according to a study published in ...
Dec 1, 2022
0
2
A vaccine (DCVax-L), trialed at King's College Hospital and other centers around the world, using patients' immune cells to target brain cancer can extend survival by many months or, in some cases, years, the final unblinded ...
Nov 21, 2022
0
82
Neoadjuvant immune checkpoint blockade (ICB) is a promising treatment for melanoma and other cancer types, and has recently been shown to provide a modest survival benefit for patients with recurrent glioblastoma. To improve ...
Jun 29, 2021
0
13
